At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICCM IceCure Medical Ltd.
Pre-Market Trading 11-26 04:05:10 EST
0.7772
+0.0650
+9.13%
High0.8296Low0.7247Vol1.77M
Open0.7290D1 Closing0.7122Amplitude14.73%
Mkt Cap43.14MTradable Cap22.29MTotal Shares55.50M
T/O1.40MT/O Rate6.19%Tradable Shares28.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
IceCure Medical’s Cryoablation Innovation Gains Momentum
TIPRANKS  ·  11-25 22:10
IceCure Medical’s Cryoablation Innovation Gains Momentum
BRIEF-Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office
Reuters  ·  11-25 21:48
BRIEF-Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office
IceCure Medical receives Notice of Allowance from Japan’s Patent Office
TIPRANKS  ·  11-25 21:35
IceCure Medical receives Notice of Allowance from Japan’s Patent Office
Icecure Medical Ltd: Terumo Corporation Plans to File for Regulatory Approval of Prosense for Breast Cancer in 2025
THOMSON REUTERS  ·  11-25 21:30
Icecure Medical Ltd: Terumo Corporation Plans to File for Regulatory Approval of Prosense for Breast Cancer in 2025
Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office
THOMSON REUTERS  ·  11-25 21:30
Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
PR Newswire  ·  11-25 21:30
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
PR Newswire  ·  11-20
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
PR Newswire  ·  11-19
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM)
Simply Wall St.  ·  11-13
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM)
Icecure Medical’s ProSense System Gains Favorable FDA Panel Recommendation and Strong Financial Position Supports Buy Rating
TIPRANKS  ·  11-10
Icecure Medical’s ProSense System Gains Favorable FDA Panel Recommendation and Strong Financial Position Supports Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Bank of America, Lucid, Pinterest
Reuters  ·  11-08
BUZZ-U.S. STOCKS ON THE MOVE-Bank of America, Lucid, Pinterest
BUZZ-IceCure up after FDA panel backs use of its breast cancer treatment system
Reuters  ·  11-08
BUZZ-IceCure up after FDA panel backs use of its breast cancer treatment system
Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.
Dow Jones  ·  11-08
Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.
IceCure Medical’s ProSense® Gains FDA Panel Support
TIPRANKS  ·  11-08
IceCure Medical’s ProSense® Gains FDA Panel Support
BRIEF-FDA Advisory Panel Backs Icecure's Prosense Cryoablation For Early-Stage Low Risk Breast Cancer
Reuters  ·  11-08
BRIEF-FDA Advisory Panel Backs Icecure's Prosense Cryoablation For Early-Stage Low Risk Breast Cancer
Icecure Medical Ltd - FDA Decision on Marketing Authorization Expected in Q1 of 2025
THOMSON REUTERS  ·  11-08
Icecure Medical Ltd - FDA Decision on Marketing Authorization Expected in Q1 of 2025
FDA Advisory Panel Votes in Favor of Icecure's Prosense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
THOMSON REUTERS  ·  11-08
FDA Advisory Panel Votes in Favor of Icecure's Prosense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
PR Newswire  ·  11-08
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
PR Newswire  ·  10-29
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
BRIEF-Icecure Receives Notice Of Allowance From U.S. Patent And Trademark Office For Its Next-Generation Cryoablation System
Reuters  ·  10-21
BRIEF-Icecure Receives Notice Of Allowance From U.S. Patent And Trademark Office For Its Next-Generation Cryoablation System
No data available

Introduction

Company Name.
IceCure Medical Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Issue price:
--